Skip to main content

Ibrutinib, Rituximab, and Lenalidomide in Treating Patients with Refractory or Recurrent, Primary or Secondary Central Nervous System Lymphoma

Trial Status: Active

This phase Ib trial studies the side effects and best dose of ibrutinib when given together with rituximab and lenalidomide in treating patients with primary or secondary central nervous system lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study is being done to find out if giving ibrutinib, rituximab, and lenalidomide is safer and works better in treating patients with primary or secondary central nervous system lymphoma compared to standard treatment.

Inclusion Criteria

  • Participants must be able to understand and be willing to sign a written informed consent document
  • Histologically documented PCNSL or histologically documented systemic diffuse large B-cell lymphoma (DLBCL)
  • Patients must have relapsed/refractory PCNSL or relapsed/refractory SCNSL
  • All patients need to have received at least one prior central nervous system (CNS) directed therapy. There is no restriction on the number of recurrences
  • Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head computed tomography [CT]) 21 days prior to study registration. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings consistent with CSF disease 21 days prior to study registration (at the discretion of the investigator)
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
  • Platelets >= 75 x 10^9/L and no platelet transfusion within the past 21 days prior to study registration
  • Hemoglobin (Hgb) >= 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registration
  • International normalized ratio (INR) =< 1.5 and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) =< 1.5 times the upper limit of normal
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 times the upper limit of normal
  • Serum bilirubin =< 1.5 times the upper limit of normal; or total bilirubin =< 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert syndrome
  • Serum creatinine =< 2 times the upper limit of normal
  • Escalation: calculated creatinine clearance (CrCl) >= 60 ml/min using the Cockcroft-Gault equation
  • Extension: calculated creatinine clearance (CrCl) >= 30 ml/min using the Cockcroft-Gault equation
  • Woman of reproductive potential must agree to use highly effective methods of birth control during the period of therapy and for 30 days after the last dose of the study drug. Men who are sexually active must agree to use highly effective contraception during the period of therapy and for 3 months after the last dose
  • Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry
  • Patients must be able to tolerate MRI/CT scans
  • Patients must be able to tolerate lumbar puncture and/or Ommaya taps
  • Participants must have recovered to grade 1 toxicity from prior therapy
  • Participants should be able to submit up to 20 unstained formalin-fixed, paraffin embedded (FFPE) slides from the initial tissue diagnosis prior to study registration for confirmation of diagnosis and correlative studies
  • All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program
  • Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
  • NOTE: Prior autologous stem cell transplant as well as prior radiation to the CNS does NOT prevent patients from enrollment into the trial

Exclusion Criteria

  • Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded
  • Patient is concurrently using other approved or investigational antineoplastic agents
  • Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy =< 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or mitomycin-C prior to starting the study drug, or the patient has not recovered from the side effects of such therapy
  • Patient has received external beam radiation therapy to the CNS within 21 days of the first dose of the study drug
  • Patient requires more than 8 mg of dexamethasone daily or the equivalent
  • Patient has an active concurrent malignancy requiring active therapy
  • The patient has been treated with radio- or toxin-immunoconjugates within 70 days of the first dose of the study drug
  • Patient is allergic to components of the study drug
  • Patient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists. Patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug. Low molecular weight heparin is allowed. Patients with congenital bleeding diathesis are excluded
  • Patient is taking a drug known to be a moderate and strong inhibitor or inducers of the P450 isoenzyme CYP3A. Participants must be off P450/CYP3A inhibitors and inducers for at least two weeks prior to starting the study drug
  • Patient is using systemic immunosuppressant therapy, including cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of > 5 mg/day or prednisone or the equivalent. Participants must be off immunosuppressant therapy for at least 28 days prior to the first dose of the study drug
  • Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, hypertension, valvular disease, pericarditis, or myocardial infarction within 6 months of screening
  • Patient has a known bleeding diathesis (e.g. von Willebrand's disease) or hemophilia
  • Patient is known to have human immunodeficiency virus (HIV) infection
  • Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests
  • Patient is known to have an uncontrolled active systemic infection
  • Patient underwent major systemic surgery =< 4 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug
  • Patient is unable to swallow capsules or has a disease or condition significantly affecting gastrointestinal function, such as malabsorption syndrome, resection of the stomach or small bowel, or complete bowel obstruction
  • Patient has poorly controlled diabetes mellitus with a glycosylated hemoglobin > 8% or poorly controlled steroid-induced diabetes mellitus with a glycosylated hemoglobin of > 8% (for patients who received a short-term, high-dose dexamethasone treatment course prior to enrollment [< 7 days], the HbA1c value can be rounded to the nearest whole number)
  • Patient has a life-threatening illness, medical condition, or organ system dysfunction that, in the opinion of the investigator, could compromise the subject's safety or put the study outcomes at undue risk
  • Women who are pregnant or nursing (lactating), where pregnancy is defined as a state of a female after conception until the termination of gestation, confirmed by a positive serum human chorionic gonadotropin (hCG) laboratory test of > 5 mIU/mL
  • Patient has undergone prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion)
  • The patient is unwell or unable to participate in all required study evaluations and procedures
  • Known hypersensitivity to ibrutinib, thalidomide or lenalidomide
  • Females who are pregnant

New Jersey

Basking Ridge
Memorial Sloan Kettering Basking Ridge
Status: ACTIVE
Contact: Christian Grommes
Phone: 212-610-0344
Middletown
Memorial Sloan Kettering Monmouth
Status: ACTIVE
Contact: Christian Grommes
Phone: 212-610-0344
Montvale
Memorial Sloan Kettering Bergen
Status: ACTIVE
Contact: Christian Grommes
Phone: 212-610-0344

New York

Commack
Memorial Sloan Kettering Commack
Status: ACTIVE
Contact: Christian Grommes
Phone: 212-610-0344
New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Christian Grommes
Phone: 212-610-0344
Uniondale
Memorial Sloan Kettering Nassau
Status: ACTIVE
Contact: Christian Grommes
Phone: 212-610-0344
West Harrison
Memorial Sloan Kettering Westchester
Status: ACTIVE
Contact: Christian Grommes
Phone: 212-610-0344

PRIMARY OBJECTIVE:

I. To define the maximum tolerated dose (MTD) of ibrutinib in combination with rituximab and lenalidomide in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) patients.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of ibrutinib in combination with rituximab and lenalidomide in PCNSL and SCNSL patients by assessing the frequency and severity of adverse events.

II. To assess the progression free survival at 16 weeks (PFS16w), 24 weeks (PFS24w) and 48 weeks (PFS48w).

III. To assess the duration of response (DOR) and overall survival (OS) in patients with PCNSL and SCNSL receiving ibrutinib, rituximab and lenalidomide.

IV. To explore the therapeutic efficacy using overall response rate (ORR) on magnetic resonance imaging (MRI) and/or cerebrospinal fluid (CSF) studies.

EXPLORATORY OBJECTIVES:

I. To correlate drug response to lymphoma subgroups and BCR signaling pathway activation status.

II. To correlate drug response to expression of cerebron.

III. To characterize mutational abnormalities and correlate with treatment response.

IV. To correlate apparent diffusion coefficient (ADC)/diffusion-weighted imaging (DWI)/perfusion MRI imaging changes to response to ibrutinib.

OUTLINE: This is a dose-escalation study of lenalidomide and ibrutinib.

Patients receive rituximab intravenously (IV) on day 1 of cycles 1-6, lenalidomide orally (PO) once daily (QD) on days 1-21 of cycles 1-12, and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Christian Grommes

  • Primary ID 18-432
  • Secondary IDs NCI-2019-02784
  • Clinicaltrials.gov ID NCT03703167